Most Cancer Patients Prepared To Delay Treatment To Benefit From Personalized Care
In patients with metastatic colorectal cancer (mCRC), the survey found that almost half remain unaware that a KRAS biomarker test can determine whether a targeted therapy could be effective for them.1
Also, 73% of mCRC patients would be willing to delay initiation of treatment by two weeks or more (the average turnaround time for KRAS test results) to be prescribed a therapy that is targeted and effective, with around a third (31%) stating they would be prepared to wait 'as long as it takes'.1 Almost three quarters (73%) of mCRC patients would be willing to undergo a re-biopsy if necessary.1
"KRAS testing and other biomarker tests can be beneficial in the management of patients, and it would be useful to have these tests conducted as early as possible," said Professor Sabine Tejpar, Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium, and lead study author. "However, this new survey shows that patients with metastatic colorectal cancer are less likely to be given a biomarker test and a targeted therapy at diagnosis than those with other cancers. This can lead to suboptimal treatment and unnecessary additional investigations, including re-biopsy, before an appropriate 1st-line targeted therapy is given."
Adapted by MNT from original media release